Romsons Temasek Jongsong Investment: TT&A, JSA Advise India Medical Devices

• Romsons Group Private Limited has secured an investment from Jongsong Investments Pte. Ltd., an indirect subsidiary of Temasek Holdings.
• TT&A advised Romsons on both the investment and the sale of shares by its promoter group and other shareholders.
• JSA Advocates & Solicitors provided legal counsel to Temasek for the transaction.
• Romsons, founded in 1952, pioneered the use of single-use disposable medical devices in India to reduce hospital infection rates.
• The investment is intended to support Romsons' expansion in the medical devices and personal care & hygiene sectors.

The Romsons Temasek Jongsong investment TT&A JSA deal is structured not only as an investment into Romsons but also involved the sale of specific shares held by the promoter group and other existing shareholders to Temasek.

Romsons Group Private Limited, a prominent player in India's medical devices sector, has successfully secured a significant investment from Jongsong Investments Pte. Ltd. This strategic capital infusion comes from an indirect wholly-owned subsidiary of Temasek Holdings (Private) Limited, signaling continued private equity interest in India's healthcare market. The Romsons Temasek Jongsong investment TT&A JSA deal is structured not only as an investment into Romsons but also involved the sale of specific shares held by the promoter group and other existing shareholders to Temasek.

This substantial Romsons private equity deal is poised to fuel the company's ambitious expansion plans. Romsons currently holds a considerable presence across both the medical devices and personal care & hygiene sectors. The fresh capital from the Jongsong Investments Romsons deal is specifically earmarked to enhance and broaden this existing market footprint, allowing Romsons to further solidify its position and reach within these critical industries.

The intricate legal aspects of this investment were navigated by leading law firms, with TT&A advising Romsons Group Private Limited throughout the process. The TT&A team provided comprehensive counsel on both the investment itself and the associated sale of shares to Temasek. Key members of the transaction team included Joint-Managing Partner Gautam Saha, Partner Shivranjani Ralawata, Managing Associate Nishant Singh, and Associate Eshani Agarwal.

Further demonstrating the multi-faceted nature of the TT&A JSA India M&A transaction, TT&A also provided specialized advice on competition law aspects. This crucial regulatory guidance was delivered by a dedicated team comprising Partner Sonam Mathur, Senior Associate Samriddha Gooptu, and Associate Indrayani Bhadra. On the investor side, JSA Advocates & Solicitors represented Temasek, ensuring their interests were meticulously addressed in this significant Temasek India medical devices investment.

Founded in 1952 by Ram Lal Khanna, Romsons has a long-standing history of innovation within the Indian healthcare landscape. The company is credited with pioneering a transformative shift in the country's medical practices by facilitating the transition from reusable surgical equipment to single-use, disposable medical devices. This pivotal change was instrumental in significantly reducing hospital infection rates across India, establishing Romsons as a key contributor to public health.

With this latest investment, Romsons is well-positioned to leverage its foundational legacy and expand its already substantial operations. The capital infusion will enable the company to further innovate and grow its offerings in both the medical devices and personal care & hygiene sectors, reinforcing its commitment to improving healthcare outcomes and consumer well-being in India. This Romsons private equity deal underscores the ongoing attractiveness of India's medical technology market to global investors.

This transaction signals continued private equity interest in India's medical devices sector, offering a precedent for deal structuring and highlighting the involvement of specific firms (TT&A, JSA) in advising on investment and competition law aspects for similar transactions. Lawyers should note the active deal flow and regulatory considerations in this growing market.

Source: Original reporting via Bar & Bench